Kindstar Globalgene Technology, Inc. (HK:9960)
:9960
Top Page
Kindstar Globalgene Technology, Inc.
(9960)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$1.00
▼(-14.53% Downside)
Action:ReiteratedDate:10/31/25
The overall stock score is primarily influenced by financial performance challenges, including declining revenue and negative cash flows. Technical analysis indicates bearish momentum, further impacting the score. Valuation concerns due to negative earnings also contribute to the cautious outlook.
Positive Factors
Balance sheet strength and low leverage
A high equity ratio and minimal debt provide durable financial resilience, allowing Kindstar to absorb revenue shocks, fund operations without heavy interest burdens, and retain strategic optionality for partnerships or targeted investments over the next several quarters.
Negative Factors
Declining revenue and negative margins
Falling top-line combined with persistent negative EBIT and net margins undermines sustainable growth and reinvestment capacity. Without revenue stabilization or margin improvement, the firm may struggle to finance expansion, retain clinical partners, and support long-term R&D or service upgrades.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength and low leverage
A high equity ratio and minimal debt provide durable financial resilience, allowing Kindstar to absorb revenue shocks, fund operations without heavy interest burdens, and retain strategic optionality for partnerships or targeted investments over the next several quarters.
Read all positive factors
Kindstar Globalgene Technology, Inc. (9960) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.20B
Dividend Yield2.02%
Average Volume (3M)956.95K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth-4.09%
EPS Growth-1242.31%
CountryHK
Employees3,011
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,041,309,900
10 Day Avg. Volume603,200
30 Day Avg. Volume956,950
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.38
Price to Sales (P/S)1.13
P/FCF Ratio-5.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model
Company Description
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and techno...
How the Company Makes Money
Kindstar Globalgene Technology generates revenue primarily through its genetic testing services, which clients pay for on a fee-for-service basis. Key revenue streams include the provision of NIPT services to expectant parents, cancer genomic prof...
Kindstar Globalgene Technology, Inc. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 911.15M | 927.57M | 967.26M | 1.39B | 930.67M | 891.39M |
| Gross Profit | 410.30M | 439.56M | 451.13M | 603.05M | 485.77M | 460.98M |
| EBITDA | -139.49M | -117.24M | 126.38M | 150.72M | -1.39B | -909.23M |
| Net Income | -102.56M | -54.59M | 41.29M | 75.46M | -1.45B | -974.02M |
Balance Sheet | ||||||
| Total Assets | 3.90B | 3.77B | 3.67B | 3.73B | 3.19B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 1.61B | 1.66B | 2.03B | 2.00B | 2.15B | 956.29M |
| Total Debt | 471.06M | 398.36M | 194.29M | 199.86M | 18.19M | 85.39M |
| Total Liabilities | 1.05B | 950.51M | 774.23M | 871.62M | 464.15M | 3.41B |
| Stockholders Equity | 2.80B | 2.78B | 2.87B | 2.83B | 2.72B | -1.84B |
Cash Flow | ||||||
| Free Cash Flow | -69.26M | -179.57M | -189.65M | -102.90M | -220.23M | 46.68M |
| Operating Cash Flow | -7.64M | -44.12M | -14.78M | 21.41M | 68.03M | 73.46M |
| Investing Cash Flow | 61.44M | -1.21B | 854.92M | -1.35B | -666.06M | -121.96M |
| Financing Cash Flow | 67.07M | 144.63M | -82.83M | 97.64M | 1.59B | 851.92M |
Kindstar Globalgene Technology, Inc. Technical Analysis
Neutral
1.17
Price Trends
1.17
Negative
1.20
Negative
1.33
Negative
Market Momentum
-0.01
Negative
51.39
Neutral
90.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Neutral. The current price of 1.17 is above the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.17, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 90.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9960.
Kindstar Globalgene Technology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$678.82M | 3.30 | 5.29% | 9.14% | 0.47% | 50.46% | |
66 Neutral | HK$1.32B | 5.35 | 18.05% | 4.37% | -3.56% | -17.45% | |
56 Neutral | HK$545.87M | 5.00 | 31.63% | ― | 2.30% | ― | |
54 Neutral | HK$263.57M | -2.55 | -25.22% | 3.16% | -21.31% | -149.92% | |
52 Neutral | HK$1.69B | 117.78 | 0.48% | 0.49% | -0.55% | 45.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$1.20B | -8.20 | -3.68% | 2.02% | -4.09% | -1242.31% |
* Healthcare Sector Average
HK:9960
Kindstar Globalgene Technology, Inc.
1.15
-0.02
-1.71%
HK:1518
New Century Healthcare Holding Co. Ltd.
0.54
-0.61
-53.04%
HK:1526
Rici Healthcare Holdings Ltd.
0.83
-0.27
-24.55%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.03
0.21
11.54%
HK:3869
Hospital Corporation of China Ltd
3.95
-2.85
-41.91%
HK:3886
Town Health International Medical Group Ltd.
0.25
0.02
8.23%
Kindstar Globalgene Technology, Inc. Corporate Events
Kindstar Globalgene Expands Stake in Huaxi Kindstar with Strategic Acquisition
Nov 25, 2025
Kindstar Globalgene Technology, Inc. has announced that its subsidiary, Wuhan Kindstar, has successfully acquired a 40% equity interest in Huaxi Kindstar from Huaxi Health Technology for RMB12,396,000. This acquisition, which was completed through...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.